Predialysis vancomycin target attainment after post-hemodialysis dosing in Kenya: a prospective observational study

Abstract Background Vancomycin dosing during intermittent hemodialysis is challenging, and access to therapeutic drug monitoring and area-under-the-curve-based dosing may be limited in resource-constrained dialysis settings. Prospective evidence on vancomycin exposure in African hemodialysis populations remains scarce. We evaluated predialysis concentrations achieved after 500- and 1000-mg post-hemodialysis dosing at a Kenyan tertiary hospital. Methods We conducted a prospective, single-centre observational study among adults receiving maintenance hemodialysis and empirical intravenous vancomycin for suspected catheter-related bloodstream infection. Participants received a post-hemodialysis dose of 500 mg or 1000 mg, as prescribed by the treating clinicians as part of routine care. Predialysis vancomycin concentrations were measured at study-designated 2-day and 3-day interdialytic intervals. Concentrations were classified relative to a study-defined reference range of 15–20 mg/L. Attainment, within-participant change, differences between dose groups, and exploratory associations with participant characteristics were evaluated. Culture results, including the organisms isolated, were summarised descriptively. Results Eighteen participants were enrolled, and 17 had evaluable concentration measurements. Mean predialysis concentrations were 8.51 mg/L (SD 5.19) and 9.52 mg/L (SD 6.04) at the 2-day and 3-day measurements, respectively. Fourteen of 17 participants (82.4%) had concentrations below 15 mg/L at each measurement, and one participant (5.9%) was within the 15–20 mg/L range at both measurements. The median paired change was + 0.60 mg/L (IQR 0.00–1.50; P = 0.002). Body weight was not associated with patient-mean concentration (Spearman ρ = 0.023; P = 0.931), and concentrations did not differ detectably between the 500- and 1000-mg groups (P = 0.397). Organisms were isolated from 12/18 participants (66.7%), all with at least one Gram-positive organism; Staphylococcus aureus was the most frequent isolate (7/18, 38.9%), and six of the seven evaluable participants with S. aureus had patient mean predialysis concentrations below 15 mg/L. Conclusions Fixed post-hemodialysis dosing frequently resulted in predialysis vancomycin concentrations below the study-defined reference range, while occasional above-range concentrations demonstrated substantial interindividual variability. Because S. aureus predominated among culture-positive participants, sustained subtherapeutic exposure is of concern not only for treatment failure but also for the selection of strains with reduced vancomycin susceptibility in hemodialysis patients. These findings support prospective evaluation of feasible concentration-guided dosing strategies for hemodialysis programmes where more sophisticated pharmacokinetic monitoring is not routinely available.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11444160/v1
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Predialysis vancomycin target attainment after post-hemodialysis dosing in Kenya: a prospective observational study

Anil Fastenau, Witness Lubomba, Benjamin Wambugu, Davis Ngarashi et al.
Research Square
Antibiotics Pharmacokinetics and Efficacy
preprint

Predialysis vancomycin target attainment after post-hemodialysis dosing in Kenya: a prospective observational study

Anil Fastenau, Witness Lubomba, Benjamin Wambugu, Davis Ngarashi, Claus A. Thomas, Seth O McLigeyo, J K Kayima, Reuben Maghembe
preprint en

Abstract

Abstract Background Vancomycin dosing during intermittent hemodialysis is challenging, and access to therapeutic drug monitoring and area-under-the-curve-based dosing may be limited in resource-constrained dialysis settings. Prospective evidence on vancomycin exposure in African hemodialysis populations remains scarce. We evaluated predialysis concentrations achieved after 500- and 1000-mg post-hemodialysis dosing at a Kenyan tertiary hospital. Methods We conducted a prospective, single-centre observational study among adults receiving maintenance hemodialysis and empirical intravenous vancomycin for suspected catheter-related bloodstream infection. Participants received a post-hemodialysis dose of 500 mg or 1000 mg, as prescribed by the treating clinicians as part of routine care. Predialysis vancomycin concentrations were measured at study-designated 2-day and 3-day interdialytic intervals. Concentrations were classified relative to a study-defined reference range of 15–20 mg/L. Attainment, within-participant change, differences between dose groups, and exploratory associations with participant characteristics were evaluated. Culture results, including the organisms isolated, were summarised descriptively. Results Eighteen participants were enrolled, and 17 had evaluable concentration measurements. Mean predialysis concentrations were 8.51 mg/L (SD 5.19) and 9.52 mg/L (SD 6.04) at the 2-day and 3-day measurements, respectively. Fourteen of 17 participants (82.4%) had concentrations below 15 mg/L at each measurement, and one participant (5.9%) was within the 15–20 mg/L range at both measurements. The median paired change was + 0.60 mg/L (IQR 0.00–1.50; P = 0.002). Body weight was not associated with patient-mean concentration (Spearman ρ = 0.023; P = 0.931), and concentrations did not differ detectably between the 500- and 1000-mg groups (P = 0.397). Organisms were isolated from 12/18 participants (66.7%), all with at least one Gram-positive organism; Staphylococcus aureus was the most frequent isolate (7/18, 38.9%), and six of the seven evaluable participants with S. aureus had patient mean predialysis concentrations below 15 mg/L. Conclusions Fixed post-hemodialysis dosing frequently resulted in predialysis vancomycin concentrations below the study-defined reference range, while occasional above-range concentrations demonstrated substantial interindividual variability. Because S. aureus predominated among culture-positive participants, sustained subtherapeutic exposure is of concern not only for treatment failure but also for the selection of strains with reduced vancomycin susceptibility in hemodialysis patients. These findings support prospective evaluation of feasible concentration-guided dosing strategies for hemodialysis programmes where more sophisticated pharmacokinetic monitoring is not routinely available.

Research Square
University of Nairobi (KE), Muhimbili University of Health and Allied Sciences (TZ), University of Bremen (DE), Kenyatta National Hospital (KE), St. Francis University College of Health and Allied Sciences (TZ)
Good health and well-being
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon